抗癌扶正方及含药血清对人肝癌细胞SMMC-7721生长的抑制作用

目的:探讨抗癌扶正方的抗肝癌作用。方法:提取抗癌扶正方,使用药物及含药血清,针对人肝癌细胞SMMC-7721,经过细胞培养,分光光度计检测抗癌扶正方对肝癌细胞生长抑制率的影响。结果:抗癌扶正方及药物血清,具有良好的抑肝癌细胞生长作用,尤以1、10mg/mL剂量组效果最佳,作用程度与化疗药物类似。结论:抗癌扶正方能够抑制人肝癌细胞SMMC-7721活性。其机制有必要进一步深入探讨。     

The role of XPB in cell apoptosis and viability and its relationship with p53, p21 and c-myc in hepatoma cells

BACKGROUND: Accumulation of DNA damage has been implicated in hepatocarcinogenesis. XPB plays a pivotal part in repairing damaged DNA. However, up to now, the biological effect of XPB on hepatoma cells remains elusive. MATERIALS AND METHODS: Here, we investigated the role of XPB in the apoptosis and the viability of hepatoma cells by using the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end-labelling and cell viability assay; we also investigated their relationship with p53, p21(waf1/cip1) and c-myc by using the RT-PCR and Western blot. RESULTS: Compared with the control cells HepG2/pcDNA3.1 or HepG2, XPB-transfected HepG2 cells (HepG2/pcDNA3.1-XPB) displayed lower viability, weaker activity and higher apoptosis index. At the same time, an increased expression of p21(waf1/cip1) mRNA, protein and p53 protein in addition to a decreased expression of c-myc mRNA and protein were detected in HepG2/pcDNA3.1-XPB cells. CONCLUSIONS: Our results indicated that XPB could inhibit the proliferation of hepatoma cells and had a positive effect on the expression of p53 and p21(waf1/cip1) but a negative effect on c-myc.     

反义寡脱氧核苷酸对人肝癌裸鼠模型生长及转移的影响

目的 观察反义Ｈ－ｒａｓ寡脱氧核苷酸（ＯＤＮ）对高表达蛋白ｐ２１Ｈ- ｒａｓ的人肝癌高转移裸鼠模型ＬＣＩ－Ｄ２０细胞生长、凋亡及转移潜能的影响。方法原代培养ＬＣＩ－Ｄ２０细胞，经１０μｍｏｌ／Ｌ浓度反义ＯＤＮ处理后，以１．５×１０细胞数分别接种于１４只裸鼠皮下缝制皮囊内：６只接种反义Ｈ－ｒａｓＯＤＮ处理细胞，４只接种Ｈ－ｒａｓ非特异性反义ＯＤＮ处理细胞，余４只接种未作处理的对照细胞。结果反义Ｈ－ｒａｓ对ＬＣＩ－Ｄ２０细胞增殖具有显著抑制作用（ｔ＝３１．５２９，Ｐ＜０．０１），反义ＯＤＮ处理细胞，Ｓ期比率（３６．０±１．４）显著低于对照组（５８．５±０．９，ｔ＝１３．５１９，Ｐ＜０．０１），而Ｇ１／Ｇ０期比率（５６．７％±１．１％）高于对照组（３７．４±０．７，ｔ＝１４．８０２，Ｐ＜０．０１）；反义Ｈ－ｒａｓＯＤＮ处理细胞的凋亡发生率（３４．０％±４．５％）显著高于对照组（２．５％±１．２％，ｔ＝１３．４３４，Ｐ＜０．０１）；反义Ｈ－ｒａｓ处理对ＬＣＩ－Ｄ２０细胞在接种动物体内的生长具有显著延迟抑制作用（ｔ＝３．５０９，ｔ＝３．４５２，Ｐ＜０．０１）；接种动物的肺转移率，反义Ｈ－ｒａｓＯＤＮ处理组显著低于对照组。     

人癌基因c—sis 的RFLP_s在肝癌和正常组织中的分布

作者用人 c-sis 基因1.7kb 探针(BamHⅠ—BamHⅠ)研究了 c-sis 基因的 RFLps在肝癌和正常组织中的分布。并首次报道 c-sis 基因对 HnidⅢ、EcoRⅠ、SacⅠ、PstⅠ、PvuⅡ和 MspⅠ六种限制酶有多态性,其中用 EcoRⅠ、PatⅠ、PvuⅡ、和 MspⅠ四种限制酶、发现的 c-sis 基因 RFLPs 在肝癌和正常组织中无明显差别。本文还对 c-sis 基因甲基化问题进行了讨论,并表明 c-sis 基因的 GGCC 顺序甲基化程度较低且无组织特异性:     

Cellular models for the screening and development of anti-hepatitis C virus agents

Investigations on the biology of hepatitis C virus (HCV) have been hampered by the lack of small animal models. Efforts have therefore been directed to designing practical and robust cellular models of human origin able to support HCV replication and production in a reproducible, reliable and consistent manner. Many different models based on different forms of virions and hepatoma or other cell types have been described including virus-like particles, pseudotyped particles, subgenomic and full length replicons, virion productive replicons, immortalised hepatocytes, fetal and adult primary human hepatocytes. This review focuses on these different cellular models, their advantages and disadvantages at the biological and experimental levels, and their respective use for evaluating the effect of antiviral molecules on different steps of HCV biology including virus entry, replication, particles generation and excretion, as well as on the modulation by the virus of the host cell response to infection.     

扶正抗癌方对大鼠移植性肝癌病理形态及超微结构的影响

目的:探讨扶正抗癌方(简称CM)对大鼠移植性肝癌病理形态学及超微结构的作用。方法:用大鼠移植性肝癌模型对CM进行研究,观察使用CM后瘤组织在光镜及电镜下的形态变化。结果:光镜下见瘤细胞肿胀、变形,轻度坏死者占6/10;中度坏死者占1/10;重度坏死者占0/10。透射电镜下见瘤细胞呈现凋亡征象。结论:CM有杀灭肿瘤细胞的作用及诱导肿瘤细胞凋亡的效应。     

核心岩藻糖化运铁蛋白测定在良,恶性肝病鉴别诊断中的初步应用

利用LCA-agarose固相亲和层析法分离血清中核心岩藻糖化的运铁蛋白（cFuc-Tf），再结合运铁蛋白免疫比浊法，测定了50例正常人、44例良性肝病患者以及19例肝癌患者血清中的核心岩藻糖化运铁蛋白。结果显示正常人、良性肝病患者以及肝癌患者血清中的CFCC-Tf分别为36±34.9mg／L、40．5±34．1mg／L和167．8±104mg／L。经统计学处理，肝癌患者血清中的cFuc-Tf含量较正常人及其它良性肝病患者有极显著的升高。以cFuc-Tf＞140．7mg／L为诊断上限时，诊断肝癌的特异性为98．9％，阳性率为579％，对伴有AFP升高（＞40pg／L）之肝癌，阳性率为100％。血清eFuc-Tf测定可作为肝癌鉴别诊断的一项新指标。     

肝节段动脉夹馅法化疗栓塞治疗肝癌

本文介绍采用肝节段动脉碘油抗癌药混合乳液夹馅法化学栓塞治疗肝癌的肤浅体会。超选择性插管的基本方法包括:(1)导管导丝一导管交换法,(2)徽导管同轴导管法。     

奥曲肽与奥美拉唑联合应用对肝癌H22生长的抑制作用

目的观察奥曲肽与奥美拉唑联合应用对肝癌H22生长的抑制作用。方法建立小鼠肝癌H22肉瘤移植模型后,随机分为阴性对照组、顺铂组、奥曲肽组、奥美拉唑组和奥曲肽＋奥美拉唑组（联合用药组）,给药后计算肿瘤生长抑制率和肿瘤微血管密度的变化。结果奥曲肽组与奥美拉唑组的抑瘤率分别为33.5%、29.6%,联合用药组的抑瘤率为37.1%,差异无统计学意义（P〉0.05）。与阴性对照组比较,奥曲肽组与奥美拉唑组能够降低小鼠肝癌H22的微血管密度,差异有统计学意义（P〈0.05）,联合用药降低更加明显,其中奥曲肽组与奥美拉唑组的微血管密度分别为（29.34±8.78）、（40.95±9.23）,联合用药组为（23.89±5.76）。结论奥曲肽联合奥美拉唑能够显著抑制肝癌H22的生长,联合用药可能具有协同效果。     

B超引导下肝癌射频消融术后观察与护理分析

目的探讨B超引导下射频消融术治疗肝癌患者的术后护理方法。方法对该院16例肝癌患者采用射频消融术进行治疗,观察术后恢复情况并总结护理方法。结果 16例患者均为第1次行经皮肝穿刺射频消融。1个月后B超复查,病灶均呈低密度改变,治疗效果良好。结论 B超引导下射频消融术治疗肝癌患者的术后加强病情观察及术后护理是保证治疗成功的关键。